Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Biosimilars Take A Bite Out Of Roche's Herceptin, But Tecentriq Surges

Risdiplam Launch Among 2020 Tests

Executive Summary

Roche's Q4 and full year results are slightly below expectations, but analysts still see it as one of sector's strong performers in 2020.

You may also be interested in...



Zolgensma Stands Out In Strong Q4 For Novartis

CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."

Is Biogen’s Aducanumab Approvable? Opinions Divided Ahead Of Review

Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but  US FDA could offer it the benefit of the doubt.

Novartis’ Cholesterol Drug Inclisiran Closes In On EU Approval

Timing means full EU approval could coincide with US FDA authorization later this year.

Topics

Related Companies

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel